Small Animal Clinical Pharmacology - CYF MEDICAL DISTRIBUTION

More documents

Recommendations

Info

INDEX J contraindications and precautions 280 formulations and dose rates 280 mechanism of action 211, 280 pharmacokinetics 211 selective toxicity 203 spectrum of activity 206, 207 Jaffe reaction, cephalosporins 168 Journals 10 online 11 K Kainate receptors 114 Kanamycin 172 Kaolin and pectin 488 Ketamine 96–97, 104–107 adverse effects 106–107, 124 clinical applications 104–105 contraindications and precautions 107 formulations and dose rates 105 mechanism of action 105 pharmacokinetics 106 Ketoconazole in adrenal dysfunction 521–522 adverse effects 49, 50, 51, 191, 522 antiprotozoal action 238 clinical applications 189, 191 contraindications 191 drug interactions 522 formulations and dose rates 522 mechanism of action 521–522 ocular therapy 567 pharmacokinetics 190, 522 Ketoprofen 293, 301 Ketorolac 305, 558 Kidney see entries beginning Renal L L-deprenyl see Selegiline L-thyroxine 499–500 L-tri-iodothyronine 499 L-type calcium channels 9, 458–459 Lactation, adverse drug reactions (ADRs) 50 Lactulose 495–496 Large intestine parasites 248–249 Latamoxef 167 Latanoprost 571 Laxatives, enemas and bowel cleansers 485–486 LD 50 6 Leflunomide 277–278 Lente insulin 511 Leukotrienes 467–468 Levamisole as anthelmintic 203, 206, 209–210 as immunostimulant 280–281 Levetiracetam 368, 379 Levothyroxine 499–500, 508 LH see Luteinizing hormone Lidocaine (lignocaine) 9, 53 adverse effects 49, 51, 428–429 as antiarrhythmic 428–429 clinical applications 428 drug interactions 429 formulations and dose rates 427, 428 local anesthetic techniques/dosages 109–110 mechanism of action 428 ocular therapy 572 special considerations 429 therapeutic drug monitoring (TDM) 37 Ligand-gated ion channel receptors 9 Ligands, receptors and 8–9 Lime sulfur 227 D-limonene 227 Linalool oil 227 Lincomycin 177 Lincosamides 151, 156, 176–178 antiprotozoal dosages 240 Lindane 203 Lineweaver–Burke plot 5 Liothyronine 499 Lipid diffusion 28–29 Lipid solubility antibacterials 151 distribution 32 Lipid theory of anesthesia 83–84 Lipopeptides 196 Lipoxygenase (LOX) 9, 288, 292 Liquid–gas interface, inhalational anesthesia 84–85 Lisinopril 384, 412, 418 Lithium 146 therapeutic drug monitoring 37 Liver blood flow 50–51 drug metabolism 50–52 function tests 127 parasites 249 see also entries beginning Hepatic Loading dose (LD) 35, 40 Local anesthetics 108–111 adverse effects 111 clinical applications 108–109, 110 comparative pharmacology 111 formulations and dose rates 109 mechanism of action 109 ocular therapy 558, 572 pharmacokinetics 110–111 techniques 109–110 Lomustine (CCNU) 336, 341–342 Loop diuretics 390–393 Loperamide 487–488 Lorazepam 134–136 in status epilepticus 374 Losartan 422 Low molecular weight heparin (LMWH) 455 LOX (lipoxygenase) 288, 292 Lubricants laxatives 486 ocular 573 Lufenuron as antifungal 196 as antiparasitic 201, 206, 222, 226 Lumbosacral epidural see Epidural Luteinizing hormone (LH) 528, 529, 531, 532 Lymphatic parasites 252 Lysine 568 M Macrocyclic lactone 210–211 Macrolides 9, 151, 156, 176–178 antiprotozoal 240 Magnesium compounds 482–483 Malathion 201 Male reproductive physiology 528 Malignant hyperthermia 88 Malnourishment, influence on pharmacokinetics 18–19, 52 Mannitol 571 Manufacturing process, new chemical entities (NCEs) 21 Marbofloxacin 51, 181–183 Maropitant 474–475 Mast cell stabilizers, ocular therapy 564 Mastitis, antibacterial drug choice 153 Material Safety Data Sheet (MSDS) 23 Maximum effect 5 Maximum tolerated dose (MTD), cancer chemotherapy 332 Meal type and size, food–drug interactions 16 Mebendazole 206, 207 Mechlorethamine 333, 345 Meclofenamic acid 301 Medetomidine 71, 120–124 atipamezol as antidote to 74 pharmacokinetics 121–122 as premedicant 315 Medical and medication errors 14–15 Medroxyprogesterone acetate 142–143, 535 Megestrol acetate 142–143, 278, 535 adverse effects 49, 278 clinical applications 278 contraindications and precautions 278 mechanism of action 278 Meglumine antimonate 9, 239, 241–242 Melarsomine hydrochloride 206, 218–219 Melatonin, and behavior 128 Meloxicam 287, 301–302 adverse effects 297, 302 clinical applications 301 formulations and dose rates 301 mechanism of action 301–302 pharmacokinetics 302 Melphalan 336, 345–346 Membrane permeation 32 Mepacrine see Quinacrine hydrochloride Meperidine (pethidine) 319, 322 Mepivacaine 109–110 583
INDEX Metabolism dogs vs cats 47 and elimination of inhalational anesthesia 87 physiological basis 32–33 Metabotropic receptors 114 Metaflumizone 204, 222, 230 Metered dose inhalers (MDI) and spacers 463 Metergoline 533, 535 Methadone 319, 322–323 Methazolamide 571 Methimazole 49 Methicillin see Meticillin S-methoprene 204, 221, 222, 225 Methotrexate 9, 336, 360–361 Methoxyflurane 93–94 adverse effects 51, 93–94 drug interactions 94 pharmacokinetics 89, 93 N-methyl-D-asparate (NMDA) see NMDA receptors Methylergometrine 543 Methylphenidate 133–134 Methylprednisolone 51 Methylxanthines 459, 461–462 Meticillin 162 resistance (MRSA) 162, 164, 165, 168, 169, 179, 181, 184 Metoclopramide 472–473, 535 Metronidazole 151, 183 adverse effects 49, 183 antiprotozoal dosages 238 clinical applications 183 dosage 156 Helicobacter species eradication 483 mechanism of action and resistance 183 pharmacokinetics 183 selective toxicity 202 spectrum of activity 183 Metyrapone 523–524 Mexiletine 385, 427, 432–433 Mezlocillin 163 MGK 264 (N-Octyl bicycloheptene dicarboximide) 202, 232 MGK 326 (Di-Npropylisocinchomeronate) 222, 232 Mibolerone 538–539 Micafungin 196 Miconazole 189 emollient 553 ocular therapy 567 Midazolam 118–120 drug interactions 191 as premedicant 315 in status epilepticus 374 Mifepristone 537–538 Milbemycin oxime 206, 213 Milbemycins 213–214 Milrinone and amrinone 400–402 Miotics 558, 569–570 Misoprostol 480–481 Mithramycin see Plicamycin Mitotane 522–523 584 Mixoxantrone (mitozantrone) 351–352 Mobility, influence on pharmacokinetics 19 Moisturizing agents 553–554 Monoamine oxidase inhibitors (MAOIs) 9, 140–141 drug interactions 141 amitraz 204 antihistamines 129, 130 SSRIs 139–140 tricyclic antidepressants 138 Monoamine oxidase (MAO) 72 Monoclonal antibody therapy 285 Montelukast 467–468 Montmorillonite 488–489 MOPP chemotherapy 365 Morphine 318–322 adverse effects 47, 48, 49, 50, 51, 320–322 clinical applications 320 contraindications and precautions 322 drug interactions 322 formulations and dose rates 320 intra-articular 317 mechanism of action 320 pharmacokinetics 320 Motility-modifying drugs 487–490 Moxidectin 206, 213–214, 222 MRSA resistance 162, 164, 165, 168, 169, 179, 181, 184 Mucolytics 465–467 Multidrug resistance protein 1 (Mdr1) 54 (see also P-glycoprotein or P-gp) Mupirocin 554 Muramyl tripeptide 282 Muscarinic acetylcholine (ACh) receptor 60–61, 65 Muscarinic agonists 67–68, 127 Muscarinic antagonists 68–69, 127 Muscarinic receptors 8, 60–61, 65, 68 airways 462 and behavior 127 drugs affecting 67–69, 127 GIT 476 Musculoskeletal system inhalational anesthesia effects 88 morphine effects 321 parasites 252 Mydriatics 558, 569 Myocardial toxicity due to doxorubicin 350 Myocardial toxicity see Digitalis toxicity N Nalbuphine 319, 328–329 Nalmefene 319, 329 Nalorphine 319, 328 Naloxone 133, 319 Naltrexone 133 Naproxen 305 adverse effects 30, 297 clinical applications 305 mechanism of action 305 pharmacokinetics 305 Narrow-spectrum penicillins 161 Natamycin 567 Natural remedies and hepatic enzymes 51 Nausea and vomiting, opioid analgesics 314, 321 Naxolone 133, 328 Neomycin 172 ocular therapy 565 Neonates adverse drug reaction (ADRs) 50 antibacterials in 152 drug metabolism in 19 Neonicotinoids 228 Neosporin ointment 564 Neostigmine 65, 78 Neuroendocrine modulation 412–418 Neuroleptanesthesia 113 Neurones, pre- and postganglionic 59–60, 61 Neurotransmission, ANS 61 Neurotransmitters ANS 61, 62–64, 69–74 CNS 113–114 enteric 60 New drugs/new chemical entities (NCEs) chemical characterization 21 development 20–22 discovery 20–21 efficacy studies 21 environmental fate and toxicity 21 heart failure 423–424 manufacturing process 21 pharmacovigilance/postmarketing experiences 22 regulatory review 22 research 21 safety 21 triazoles 193–194 New Zealand, reporting adverse drug reactions (ADRs) 57 Niacinamide 279 Nicergoline 144 Niclosamide 201, 206, 207, 215–216 Nicotinic acetylcholine receptor nAChR 61, 65, 203 Nicotinic agonists 66–67 Nicotinic antagonists 67, 75–78 Nicotinic anthelmintics 208–210 Nicotinic receptors 9, 61, 65, 66 Nifurtimox 203, 238, 243 Nikkomycin Z 196 Nikkomycins 196 Nitenpyram 203, 228 Nitrate tolerance 408 Nitrates 408–411 Nitric oxide (NO) 60–61, 64, 65 Nitrofurans 184–185, 238 Nitrofurantoin 156, 184–185 Nitroglycerin 385, 403, 408–409 paste 386 Nitroimidazole 238 Nitroprusside 403, 408, 410–411 Nitroscanate 206, 220–221
Page 1 and 2:
An imprint of Elsevier Limited © E
Page 3 and 4:
CONTRIBUTORS Matthias J Kleinz Depa
Page 5 and 6:
Dedication To Tom, Rosalind and Jim
Page 7 and 8:
CHAPTER 1 PRINCIPLES OF CLINICAL PH
Page 9 and 10:
Page 11 and 12:
Page 13 and 14:
Page 15 and 16:
Page 17 and 18:
Page 19 and 20:
Page 21 and 22:
Page 23 and 24:
Page 25 and 26:
Page 27 and 28:
Page 29 and 30:
Page 31 and 32:
Page 33 and 34:
CHAPTER 2 CLINICAL PHARMACOKINETICS
Page 35 and 36:
Page 37 and 38:
Page 39 and 40:
Page 41 and 42:
Page 43 and 44:
Page 45 and 46:
Page 47 and 48:
CHAPTER 3 ADVERSE DRUG REACTIONS Un
Page 49 and 50:
CHAPTER 3 ADVERSE DRUG REACTIONS to
Page 51 and 52:
CHAPTER 3 ADVERSE DRUG REACTIONS
Page 53 and 54:
CHAPTER 3 ADVERSE DRUG REACTIONS He
Page 55 and 56:
CHAPTER 3 ADVERSE DRUG REACTIONS an
Page 57 and 58:
CHAPTER 3 ADVERSE DRUG REACTIONS wh
Page 59 and 60:
CHAPTER 3 ADVERSE DRUG REACTIONS at
Page 61 and 62:
CHAPTER 3 ADVERSE DRUG REACTIONS Ps
Page 63 and 64:
CHAPTER 3 ADVERSE DRUG REACTIONS su
Page 65 and 66:
CHAPTER 4 THE PHARMACOLOGY OF THE A
Page 67 and 68:
Page 69 and 70:
Page 71 and 72:
Page 73 and 74:
Page 75 and 76:
Page 77 and 78:
Page 79 and 80:
Page 81 and 82:
Page 83 and 84:
Page 85 and 86:
Page 87 and 88:
Page 89 and 90:
CHAPTER 5 ANESTHETIC AGENTS However
Page 91 and 92:
CHAPTER 5 ANESTHETIC AGENTS The gre
Page 93 and 94:
CHAPTER 5 ANESTHETIC AGENTS Table 5
Page 95 and 96:
CHAPTER 5 ANESTHETIC AGENTS doses.
Page 97 and 98:
CHAPTER 5 ANESTHETIC AGENTS ● hig
Page 99 and 100:
CHAPTER 5 ANESTHETIC AGENTS concent
Page 101 and 102:
CHAPTER 5 ANESTHETIC AGENTS X R 3 C
Page 103 and 104:
CHAPTER 5 ANESTHETIC AGENTS Emergen
Page 105 and 106:
CHAPTER 5 ANESTHETIC AGENTS inhalat
Page 107 and 108:
CHAPTER 5 ANESTHETIC AGENTS and enh
Page 109 and 110:
CHAPTER 5 ANESTHETIC AGENTS ● Exc
Page 111 and 112:
CHAPTER 5 ANESTHETIC AGENTS Pharmac
Page 113 and 114:
CHAPTER 5 ANESTHETIC AGENTS Central
Page 115 and 116:
CHAPTER 5 ANESTHETIC AGENTS Table 5
Page 117 and 118:
CHAPTER 5 ANESTHETIC AGENTS FURTHER
Page 119 and 120:
CHAPTER 6 SEDATIVES ● noradrenali
Page 121 and 122:
CHAPTER 6 SEDATIVES treatment, with
Page 123 and 124:
CHAPTER 6 SEDATIVES Benzodiazepines
Page 125 and 126:
CHAPTER 6 SEDATIVES It is not misci
Page 127 and 128:
CHAPTER 6 SEDATIVES respectively. H
Page 129 and 130:
CHAPTER 6 SEDATIVES Table 6.1 Sugge
Page 131 and 132:
7 Behavior-modifying drugs Kersti S
Page 133 and 134:
CHAPTER 7 BEHAVIOR-MODIFYING DRUGS
Page 135 and 136:
Page 137 and 138:
Page 139 and 140:
Page 141 and 142:
Page 143 and 144:
Page 145 and 146:
Page 147 and 148:
Page 149 and 150:
Page 151 and 152:
Page 153 and 154:
8 Antibacterial drugs Jill E Maddis
Page 155 and 156:
CHAPTER 8 ANTIBACTERIAL DRUGS phary
Page 157 and 158:
CHAPTER 8 ANTIBACTERIAL DRUGS dose
Page 159 and 160:
CHAPTER 8 ANTIBACTERIAL DRUGS Table
Page 161 and 162:
Page 163 and 164:
CHAPTER 8 ANTIBACTERIAL DRUGS Bacte
Page 165 and 166:
CHAPTER 8 ANTIBACTERIAL DRUGS lacta
Page 167 and 168:
CHAPTER 8 ANTIBACTERIAL DRUGS Antis
Page 169 and 170:
CHAPTER 8 ANTIBACTERIAL DRUGS intri
Page 171 and 172:
Page 173 and 174:
CHAPTER 8 ANTIBACTERIAL DRUGS inter
Page 175 and 176:
CHAPTER 8 ANTIBACTERIAL DRUGS Teico
Page 177 and 178:
CHAPTER 8 ANTIBACTERIAL DRUGS less
Page 179 and 180:
CHAPTER 8 ANTIBACTERIAL DRUGS Diffe
Page 181 and 182:
CHAPTER 8 ANTIBACTERIAL DRUGS forms
Page 183 and 184:
CHAPTER 8 ANTIBACTERIAL DRUGS ● I
Page 185 and 186:
CHAPTER 8 ANTIBACTERIAL DRUGS In an
Page 187 and 188:
CHAPTER 8 ANTIBACTERIAL DRUGS ● R
Page 189 and 190:
CHAPTER 8 ANTIBACTERIAL DRUGS RIFAM
Page 191 and 192:
9 Systemic antifungal therapy Josep
Page 193 and 194:
CHAPTER 9 SYSTEMIC ANTIFUNGAL THERA
Page 195 and 196:
Page 197 and 198:
Page 199 and 200:
Page 201 and 202:
Page 203 and 204:
10 Antiparasitic drugs Stephen W Pa
Page 205 and 206:
CHAPTER 10 ANTIPARASITIC DRUGS ●
Page 207 and 208:
CHAPTER 10 ANTIPARASITIC DRUGS Tabl
Page 209 and 210:
Page 211 and 212:
Page 213 and 214:
Page 215 and 216:
CHAPTER 10 ANTIPARASITIC DRUGS leva
Page 217 and 218:
CHAPTER 10 ANTIPARASITIC DRUGS ●
Page 219 and 220:
CHAPTER 10 ANTIPARASITIC DRUGS Adve
Page 221 and 222:
CHAPTER 10 ANTIPARASITIC DRUGS Mech
Page 223 and 224:
CHAPTER 10 ANTIPARASITIC DRUGS Form
Page 225 and 226:
CHAPTER 10 ANTIPARASITIC DRUGS Mech
Page 227 and 228:
Page 229 and 230:
CHAPTER 10 ANTIPARASITIC DRUGS prod
Page 231 and 232:
CHAPTER 10 ANTIPARASITIC DRUGS Lufe
Page 233 and 234:
CHAPTER 10 ANTIPARASITIC DRUGS Adve
Page 235 and 236:
CHAPTER 10 ANTIPARASITIC DRUGS 62.5
Page 237 and 238:
CHAPTER 10 ANTIPARASITIC DRUGS incr
Page 239 and 240:
CHAPTER 10 ANTIPARASITIC DRUGS rest
Page 241 and 242:
CHAPTER 10 ANTIPARASITIC DRUGS The
Page 243 and 244:
CHAPTER 10 ANTIPARASITIC DRUGS 238
Page 245 and 246:
Page 247 and 248:
CHAPTER 10 ANTIPARASITIC DRUGS In a
Page 249 and 250:
CHAPTER 10 ANTIPARASITIC DRUGS func
Page 251 and 252:
CHAPTER 10 ANTIPARASITIC DRUGS Para
Page 253 and 254:
Page 255 and 256:
Page 257 and 258:
Page 259 and 260:
Page 261 and 262:
Page 263 and 264:
Page 265 and 266:
Page 267 and 268:
CHAPTER 11 GLUCOCORTICOSTEROIDS AND
Page 269 and 270:
Page 271 and 272:
Page 273 and 274:
Page 275 and 276:
12 Immunomodulatory therapy Michael
Page 277 and 278:
CHAPTER 12 IMMUNOMODULATORY THERAPY
Page 279 and 280:
Page 281 and 282:
Page 283 and 284:
Page 285 and 286:
Page 287 and 288:
Page 289 and 290:
Page 291 and 292:
Page 293 and 294:
CHAPTER 13 NONSTEROIDAL ANTI-INFLAM
Page 295 and 296:
Page 297 and 298:
Page 299 and 300:
Page 301 and 302:
Page 303 and 304:
Page 305 and 306:
Page 307 and 308:
Page 309 and 310:
Page 311 and 312:
Page 313 and 314:
Page 315 and 316:
CHAPTER 14 OPIOID ANALGESICS inflam
Page 317 and 318:
A Agonist opioid (morphine) B Parti
Page 319 and 320:
CHAPTER 14 OPIOID ANALGESICS admini
Page 321 and 322:
CHAPTER 14 OPIOID ANALGESICS may ac
Page 323 and 324:
CHAPTER 14 OPIOID ANALGESICS Small
Page 325 and 326:
CHAPTER 14 OPIOID ANALGESICS Clinic
Page 327 and 328:
CHAPTER 14 OPIOID ANALGESICS Contra
Page 329 and 330:
CHAPTER 14 OPIOID ANALGESICS respon
Page 331 and 332:
CHAPTER 14 OPIOID ANALGESICS Advers
Page 333 and 334:
CHAPTER 14 OPIOID ANALGESICS Advers
Page 335 and 336:
15 Cancer chemotherapy Jane M Dobso
Page 337 and 338:
CHAPTER 15 CANCER CHEMOTHERAPY to m
Page 339 and 340:
CHAPTER 15 CANCER CHEMOTHERAPY curr
Page 341 and 342:
CHAPTER 15 CANCER CHEMOTHERAPY Tabl
Page 343 and 344:
CHAPTER 15 CANCER CHEMOTHERAPY Clin
Page 345 and 346:
CHAPTER 15 CANCER CHEMOTHERAPY sion
Page 347 and 348:
CHAPTER 15 CANCER CHEMOTHERAPY In t
Page 349 and 350:
CHAPTER 15 CANCER CHEMOTHERAPY afte
Page 351 and 352:
CHAPTER 15 CANCER CHEMOTHERAPY Phar
Page 353 and 354:
CHAPTER 15 CANCER CHEMOTHERAPY Form
Page 355 and 356:
CHAPTER 15 CANCER CHEMOTHERAPY conc
Page 357 and 358:
CHAPTER 15 CANCER CHEMOTHERAPY ●
Page 359 and 360:
CHAPTER 15 CANCER CHEMOTHERAPY Phar
Page 361 and 362:
CHAPTER 15 CANCER CHEMOTHERAPY in t
Page 363 and 364:
CHAPTER 15 CANCER CHEMOTHERAPY Adve
Page 365 and 366:
CHAPTER 15 CANCER CHEMOTHERAPY best
Page 367 and 368:
CHAPTER 15 CANCER CHEMOTHERAPY Form
Page 369 and 370:
CHAPTER 15 CANCER CHEMOTHERAPY baso
Page 371 and 372:
CHAPTER 15 CANCER CHEMOTHERAPY D-MA
Page 373 and 374:
CHAPTER 16 ANTICONVULSANT DRUGS sei
Page 375 and 376:
CHAPTER 16 ANTICONVULSANT DRUGS bit
Page 377 and 378:
CHAPTER 16 ANTICONVULSANT DRUGS Kno
Page 379 and 380:
CHAPTER 16 ANTICONVULSANT DRUGS Mec
Page 381 and 382:
CHAPTER 16 ANTICONVULSANT DRUGS rap
Page 383 and 384:
CHAPTER 16 ANTICONVULSANT DRUGS exc
Page 385 and 386:
17 Drugs used in the management of
Page 387 and 388:
CHAPTER 17 DRUGS USED IN THE MANAGE
Page 389 and 390:
Page 391 and 392:
Page 393 and 394:
Page 395 and 396:
Page 397 and 398:
Page 399 and 400:
Page 401 and 402:
Page 403 and 404:
Page 405 and 406:
Page 407 and 408:
Page 409 and 410:
Page 411 and 412:
Page 413 and 414:
Page 415 and 416:
Page 417 and 418:
Page 419 and 420:
Page 421 and 422:
Page 423 and 424:
Page 425 and 426:
Page 427 and 428:
Page 429 and 430:
Page 431 and 432:
Page 433 and 434:
Page 435 and 436:
Page 437 and 438:
Page 439 and 440:
Page 441 and 442:
Page 443 and 444:
Page 445 and 446:
Page 447 and 448:
Page 449 and 450:
Page 451 and 452:
Page 453 and 454:
Page 455 and 456:
Page 457 and 458:
Page 459 and 460:
Page 461 and 462:
Page 463 and 464:
Page 465 and 466:
Page 467 and 468:
Page 469 and 470:
Page 471 and 472:
Page 473 and 474:
Page 475 and 476:
CHAPTER 19 GASTROINTESTINAL DRUGS C
Page 477 and 478:
CHAPTER 19 GASTROINTESTINAL DRUGS r
Page 479 and 480:
CHAPTER 19 GASTROINTESTINAL DRUGS
Page 481 and 482:
CHAPTER 19 GASTROINTESTINAL DRUGS c
Page 483 and 484:
CHAPTER 19 GASTROINTESTINAL DRUGS w
Page 485 and 486:
Page 487 and 488:
CHAPTER 19 GASTROINTESTINAL DRUGS F
Page 489 and 490:
CHAPTER 19 GASTROINTESTINAL DRUGS i
Page 491 and 492:
CHAPTER 19 GASTROINTESTINAL DRUGS L
Page 493 and 494:
CHAPTER 19 GASTROINTESTINAL DRUGS P
Page 495 and 496:
CHAPTER 19 GASTROINTESTINAL DRUGS F
Page 497 and 498:
Page 499 and 500:
CHAPTER 19 GASTROINTESTINAL DRUGS Z
Page 501 and 502:
CHAPTER 19 GASTROINTESTINAL DRUGS
Page 503 and 504:
Page 505 and 506:
Page 507 and 508:
Page 509 and 510:
Page 511 and 512:
Page 513 and 514:
Page 515 and 516:
CHAPTER 21 DRUGS USED IN THE TREATM
Page 517 and 518:
Page 519 and 520:
Page 521 and 522:
Page 523 and 524:
Page 525 and 526:
Page 527 and 528:
Page 529 and 530:
Page 531 and 532:
Page 533 and 534:
23 Drugs and reproduction Philip G
Page 535 and 536:
CHAPTER 23 DRUGS AND REPRODUCTION I
Page 537 and 538: CHAPTER 23 DRUGS AND REPRODUCTION F
Page 539 and 540: CHAPTER 23 DRUGS AND REPRODUCTION C
Page 541 and 542: CHAPTER 23 DRUGS AND REPRODUCTION M
Page 545 and 546: CHAPTER 23 DRUGS AND REPRODUCTION n
Page 547 and 548: CHAPTER 23 DRUGS AND REPRODUCTION E
Page 551 and 552: 24 Topical dermatological therapy R
Page 553 and 554: CHAPTER 24 TOPICAL DERMATOLOGICAL T
Page 563 and 564: CHAPTER 25 OCULAR CLINICAL PHARMACO
Page 579 and 580: Index A α-adrenergic receptors 70,
Page 581 and 582: INDEX Antiplatelet drugs 456-457 pi
Page 583 and 584: INDEX Ceftazidime 168 Ceftiofur 166
Page 585 and 586: INDEX Drug receptors 4-8 Drug-drug
Page 587: INDEX Hepatic excretion 33 Hepatic
Page 591 and 592: INDEX Pentazocine 319, 327 Pentobar
Page 593 and 594: INDEX Semicarbazone 230 Septic arth
show all

Small Animal Clinical Pharmacology - CYF MEDICAL DISTRIBUTION

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?